REFERENCES
1. Luettel DM, Terluk MR, Roh J, Weinreb NJ, Kartha RV. Emerging biomarkers in Gaucher disease. In: Makowski GS, Editor. Advances in clinical chemistry. Elsevier; 2025. pp. 1-56.
2. Eijk M, Ferraz MJ, Boot RG, Aerts JMFG. Lyso-glycosphingolipids: presence and consequences. Essays Biochem. 2020;64:565-78.
3. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem. 1982;39:709-18.
4. Orvisky E, Park JK, LaMarca ME, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab. 2002;76:262-70.
5. Dekker N, van Dussen L, Hollak CE, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118-27.
6. Curado F, Rösner S, Zielke S, et al.; LYSO-PROOF Study Group. Insights into the value of Lyso-Gb1 as a predictive biomarker in treatment-naïve patients with Gaucher disease type 1 in the LYSO-PROOF study. Diagnostics. 2023;13:2812.
7. Rolfs A, Giese AK, Grittner U, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One. 2013;8:e79732.
8. Zimran A, Revel-Vilk S, Dinur T, et al. Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher outcome survey. Orphanet J Rare Dis. 2025;20:43.
9. Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat. 2010;31:1240-50.
10. Balwani M, Fuerstman L, Kornreich R, Edelmann L, Desnick RJ. Type 1 Gaucher disease: significant disease manifestations in “asymptomatic” homozygotes. Arch Intern Med. 2010;170:1463-9.
11. Fan J, Hale VL, Lelieveld LT, et al. Gaucher disease protects against tuberculosis. Proc Natl Acad Sci U S A. 2023;120:e2217673120.
12. Grabowski GA, Kishnani PS, Alcalay RN, et al. Challenges in Gaucher disease: perspectives from an expert panel. Mol Genet Metab. 2025;145:109074.
13. Mehta A, Kuter DJ, Salek SS, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. Intern Med J. 2019;49:578-91.
14. Castillon G, Chang SC, Moride Y. Global Incidence and prevalence of Gaucher disease: a targeted literature review. J Clin Med. 2022;12:85.
15. Mehta A, Belmatoug N, Bembi B, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;122:122-9.
16. Nishimura S, Ma C, Sidransky E, Ryan E. Obstacles to early diagnosis of Gaucher disease. Ther Clin Risk Manag. 2025;21:93-101.
17. Fairley C, Zimran A, Phillips M, et al. Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. J Inherit Metab Dis. 2008;31:738-44.
18. Grabowski GKE, Weinreb N. Gaucher disease: phenotypic and genetic variation. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2006.
19. Weinreb NJ, Aggio MC, Andersson HC, et al.; International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41:15-22.
20. Kaplan P, Baris H, De Meirleir L, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 2013;172:447-58.
21. Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr. 2004;144:112-20.
22. Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr. 2004;163:67-75.
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-81.
24. Harris PA, Taylor R, Minor BL, et al.; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
25. Beasley J, McCaw P, Zhang H, Young SP, Stiles AR. Combined analysis of plasma or serum glucosylsphingosine and globotriaosylsphingosine by UPLC-MS/MS. Clin Chim Acta. 2020;511:132-7.
26. Weinreb NJ, Cappellini MD, Cox TM, et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med. 2010;12:44-51.
27. Kishnani PS, Al-Hertani W, Balwani M, et al. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: results from a Delphi consensus. Mol Genet Metab. 2022;135:154-62.
28. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore). 1992;71:337-53.
29. Dinur T, Zimran A, Becker-Cohen M, et al. Long term follow-up of 103 untreated adult patients with type 1 Gaucher disease. J Clin Med. 2019;8:1662.
30. Yoldaş Çelik M, Canda E, Yazıcı H, et al. Insights into skeletal involvement in adult Gaucher disease: a single-center experience. J Bone Miner Metab. 2025;43:166-73.
31. Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009;84:208-14.
32. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82:697-701.
33. Orenstein M, Barbouth D, Bodamer OA, Weinreb NJ. Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes. Orphanet J Rare Dis. 2014;9:45.
34. Marcucci G, Brandi ML. The diagnosis and therapy of osteoporosis in Gaucher disease. Calcif Tissue Int. 2025;116:31.
35. Di Rocco M, Di Fonzo A, Barbato A, et al. Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives? Orphanet J Rare Dis. 2020;15:262.
36. Rana HQ, Balwani M, Bier L, Alcalay RN. Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genet Med. 2013;15:146-9.
37. Vieira SRL, Mezabrovschi R, Toffoli M, et al. Consensus guidance for genetic counseling in GBA1 variants: a focus on Parkinson’s disease. Mov Disord. 2024;39:2144-54.
38. Rossi M, Schaake S, Usnich T, et al. Classification and genotype-phenotype relationships of GBA1 variants: MDSGene systematic review. Mov Disord. 2025;40:605-18.
